Pharmacokinetic Study of Oral (14)C-Radiolabeled Hyzetimibe, A New Cholesterol Absorption Inhibitor

Background and objectives: Hyzetimibe is a candidate drug being investigated as the second-in-class cholesterol absorption inhibitor; it lowers plasma levels of low-density lipoprotein cholesterol (LDL-C) by blocking the Niemann-Pick C1-like 1 protein, a transporter mainly expressed in the intestine...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Jianwei, Wang, Xin, Li, Zhenyu, Ouyang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194275/
https://www.ncbi.nlm.nih.gov/pubmed/34122085
http://dx.doi.org/10.3389/fphar.2021.665372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194275/
https://www.ncbi.nlm.nih.gov/pubmed/34122085
http://dx.doi.org/10.3389/fphar.2021.665372

Ejemplares similares